Wegovy, Ozempic (Semaglutide), Mounjaro and Yurpeak (Tirzepatide), like medications, are effective in managing type 2 diabetes and obesity. Can these medications also help with asthma symptoms? 

Asthma is a chronic inflammatory disease of the airways. It causes symptoms like wheezing, coughing, chest tightness, and shortness of breath.

Research shows that people with obesity and metabolic syndrome are more likely to have asthma, as it’s often more severe and less responsive to standard treatments.

The condition involves inflammation of the airways and increased mucus production, and airway constriction. 

So, what is the connection between Wegovy, Ozempic, and Mounjaro, like medications and lung function?

GLP-1 receptors aren’t limited to the pancreas; they are also found in the lungs, airway epithelium, and immune cells. This abundance of GLP-1 receptors in the lung tissues suggests that the respiratory system may be particularly responsive to Wegovy, Ozempic, and Mounjaro, like medications. 

Another study suggests that Wegovy, Ozempic, and Mounjaro, like medications, help reduce airway inflammation and mucus secretion through mechanisms involving the inhibition of the NF-κB pathway and activation of protein kinase A. It also reveals that GLP-1 may reduce eosinophilic activation and modulate inflammation driven by advanced glycation end-products and their receptor, which are known contributors to asthma pathogenesis. These findings highlight the potential of Wegovy, Ozempic, and Mounjaro, like medications, to target key inflammatory pathways involved in asthma. 

Beyond inflammation, there is another key pathway between the GLP-1-arginine-AGE-RAGE axis. 

In obesity and metabolic syndrome, arginine metabolism is disrupted, and advanced glycation end products or advanced glycation end products (AGE) accumulate. These AGEs trigger inflammation via the RAGE receptor, worsening asthma. BUT Wegovy, Ozempic, and Mounjaro, like medications, may help by reducing AGE formation, blocking REGA activity, and restoring healthy arginine metabolism. This makes GLP-1 drugs especially promising for people with obesity-related asthma, where traditional treatments.

So, can Wegovy, Ozempic, and Mounjaro, like medications, help with asthma? 

The evidence shows that it can help people with obesity related asthma. However, it is early-stage evidence; more randomised controlled trials are needed before Wegovy, Ozempic, and Mounjaro, like medications, can be recommended as a frontline treatment for asthma. Don’t make changes to your medications without medical advice; always consult your doctor or respiratory specialist to understand what is right for you.